Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Yutaka Ariki is active.

Publication


Featured researches published by Yutaka Ariki.


Cancer Science | 2006

Possible tumor development from double positive foci for TGF-alpha and GST-P observed in early stages on rat hepatocarcinogenesis

Mitsuaki Kitano; Jutaro Wada; Yutaka Ariki; Masanori Kato; Hideki Wanibuchi; Keiichirou Morimura; Takayoshi Hidaka; Kazunori Hosoe; Shoji Fukushima

Expression of TGF‐α during promotion of neoplastic development from GST‐P‐positive foci in rat chemical hepatocarcinogenesis was investigated. One‐hundred male F344 rats were given a single intraperitoneal injection of DEN (200 mg/kg bodyweight) and subjected to two‐thirds partial hepatectomy at week 3. Commencing 2 weeks from the start, PB at doses of 0 or 500 p.p.m. was fed to the rats for 46 weeks. Groups of 10 rats were killed at weeks 4, 8, 16, 32, 48 and their livers were immunohistochemically examined for expression of GST‐P and TGF‐α. TGF‐α‐positive foci and single positive cells were observed from week 4, partially overlapping with GST‐P‐positive foci but being much fewer. Numbers of TGF‐α‐positive lesions did not increase from weeks 4–48, but their areas showed increment at weeks 32 and 48, especially with PB administration. Almost all of the tumors observed at weeks 16, 32 and 48 were positive for TGF‐α (98%). In addition, epidermal growth factor receptor overexpression was observed in most TGF‐α‐positive lesions (foci and tumors). The proliferating cell nuclear antigen labeling index in double positive foci for GST‐P and TGF‐α was significantly higher than that in TGF‐α‐negative foci. In conclusion, TGF‐α may be closely related with promotion from altered foci to neoplasms in rat hepatocarcinogenesis. Our data suggest that double positive foci for GST‐P and TGF‐α in the early stages of rat hepatocarcinogenesis may develop into tumors with promotion. (Cancer Sci 2006; 97: 478 – 483)


Archive | 1988

Hydroxystyrene compounds which are useful as tyrosine kinase inhibitors

Tadayoshi Shiraishi; Keiji Kameyama; Takeshi Domoto; Naohiro Imai; Yoshio Shimada; Yutaka Ariki; Kazunori Hosoe; Masaji Kawatsu; Ikuo Katsumi; Takayoshi Hidaka; Kiyoshi Watanabe


Biological & Pharmaceutical Bulletin | 1999

Suppressive Activity of Lycoricidinol (Narciclasine) against Cytotoxicity of Neutrophil-Derived Calprotectin, and Its Suppressive Effect on Rat A djuvant Arthritis Model

Masaaki Mikami; Mikio Kitahara; Mitsuaki Kitano; Yutaka Ariki; Yoshihiro Mimaki; Yutaka Sashida; Masatoshi Yamazaki; Satoru Yui


Archive | 1990

Hydroxystyrene compounds which have useful pharmaceutical utility

Tadayoshi Shiraishi; Keiji Kameyama; Takeshi Domoto; Naohiro Imai; Yoshio Shimada; Yutaka Ariki; Kazunoro Hosoe; Masaji Kawatsu; Ikuo Katsumi; Takayoshi Hidaka; Kiyoshi Watanabe


Archive | 1985

3,5-DIISOPROPYLBENZYLIDENE HETEROCYCLIC COMPOUND

Yutaka Ariki; Naohiro Imai; Ikuo Katsumi; Tadayoshi Shiraishi; Katsuji Yamashita; Toshiaki Yamashita


Japanese Journal of Pharmacology | 1984

Pharmacological properties of a new anti-inflammatory compound, α-(3,5-di-tert-butyl-4-hydroxybenzylidene)-γ-butyrolactone (KME-4), and its inhibitory effects on prostaglandin synthetase and 5-lipoxygenase

Takayoshi Hidaka; Kazunori Hosoe; Yutaka Ariki; Kazuyuki Takeo; Toshiaki Yamashita; Ikuo Katsumi; Hideo Kondo; Katsuji Yamashita; Kiyoshi Watanabe


Archive | 1990

1-phenyl-3,5-pyrazolidinedione hydroxystyrene compounds which have tyrosine kinase inhibiting activity

Tadayoshi Shiraishi; Keiji Kameyama; Takeshi Domoto; Naohiro Imai; Yoshio Shimada; Yutaka Ariki; Kazunori Hosoe; Masaji Kawatsu; Ikuo Katsumi; Takayoshi Hidaka; Kiyoshi Watanabe


Archive | 1991

Hydroxystyrene compounds having tyrosine kinase inhibiting activity

Tadayoshi Shiraishi; Keiji Kameyama; Takeshi Domoto; Naohiro Imai; Yoshio Shimada; Yutaka Ariki; Kazunori Hosoe; Masaji Kawatsu; Ikuo Katsumi; Takayoshi Hidaka; Kiyoshi Watanabe


Archive | 1982

3,5-DI-TERT-BUTYLSTYRENE DERIVATIVES, PROCESSES FOR THEIR PREPARATIONS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Ikuo Katsumi; Hideo Kondo; Katsuji Yamashita; Takayoshi Hidaka; Kazunori Hosoe; Yutaka Ariki; Toshiaki Yamashita; Kiyoshi Watanabe


Archive | 1982

3,5-di-Tert-butylstyrene derivatives, salts thereof, and pharmaceutical compositions containing the same as an active ingredient

Ikuo Katsumi; Hideo Kondo; Katsuji Yamashita; Takayoshi Hidaka; Kazunori Hosoe; Yutaka Ariki; Toshiaki Yamashita; Kiyoshi Watanabe

Collaboration


Dive into the Yutaka Ariki's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge